To further address which marker is the best to identify NSCLC TICs, we performed a side-by-side comparison of the tumorigenic potential among α2δ1+, CD133+, and CD166+ A549 cells in NOD-SCID mice. This evidence concerns the gene ALCAM and non-small cell lung carcinoma.